Healthcare
Opthea Ltd.(CKDXF)
Live Price
Offline$0.01
+0.00% today
1Y Change
-97.73%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $590.00M
- Revenue Growth
- -79.9%
- EPS Growth
- +62.9%
- Dividend Yield
- 0.0%
Coverage: 254 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Opthea Ltd. (CKDXF) is a Healthcare stock with a market cap of $590.00M and listed on OTC. The stock last traded around $0.01 and down 97.7% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -79.9%, EPS growth of +62.9%, a dividend yield of 0.0%. What stands out right now is revenue -79.9%, EPS +62.9%, free cash flow +1.5% with operating margin -61041.6% and ROIC -308.0%. Valuation already assumes a fairly strong business story at price/sales 2453.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CKDXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-79.9% vs +7.6% peer median
Operating Margin
Below sector median
-61041.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 26, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -79.9% and EPS is at +62.9%, with operating margin around -61041.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 26, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Aug 28, 2025 | -197.0% | +0.0% | +0.0% | +0.0% |
2025 Feb 26, 2025 | -41.9% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
CKDXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CKDXF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CKDXF Max Drawdown
-97.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CKDXF and SPY.
Company Overview
Opthea Ltd.
OTC
Opthea Ltd. is a biotechnology company focused on developing novel therapies for eye disorders. It aims to address unmet medical needs in treating retinal diseases, with a particular focus on age-related macular degeneration (AMD) and diabetic macular edema (DME). The company is dedicated to its flagship product, a biologic development known as OPT-302, which is designed to inhibit VEGF-C/D, a pathway commonly associated with the growth of abnormal blood vessels and increased vascular permeability in the eye. Targeting this pathway offers a complementary mechanism to existing anti-VEGF therapies, potentially enhancing treatment efficacy. Operating within the pharmaceutical and biotechnology industry, Opthea Ltd. plays a pivotal role in the ophthalmic sector, contributing to advancements in ocular therapeutics. Its research and development efforts are significant as they strive to improve patient outcomes in conditions leading to vision loss, influencing the broader market of retinal disease treatments.
- Leadership
- Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
- Employees
- 33
- Street Address
- Level 9, 505 Little Collins Street
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, Australia
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2453.2
- Price/Book
- โ
Growth
- Revenue
- -79.9%
- EPS
- +62.9%
- Free Cash Flow
- +1.5%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -61041.6%
- Net Margin
- -101412.0%
- ROE
- 132.4%
- ROIC
- -308.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.22
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.